Protagonist Therapeutics, Inc. (PTGX) Short Interest Update
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) was the recipient of a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 257,753 shares, an increase of 8.5% from the May 15th total of 237,623 shares. Based on an average trading volume of 347,545 shares, the days-to-cover ratio is currently 0.7 days.
A number of research analysts have issued reports on PTGX shares. Zacks Investment Research downgraded shares of Protagonist Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, April 12th. BMO Capital Markets upped their target price on shares of Protagonist Therapeutics from $34.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday, May 31st.
Institutional investors have recently bought and sold shares of the company. Teachers Advisors LLC raised its position in Protagonist Therapeutics by 17.7% in the fourth quarter. Teachers Advisors LLC now owns 9,461 shares of the company’s stock valued at $208,000 after buying an additional 1,424 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Protagonist Therapeutics by 15.1% in the first quarter. Bank of New York Mellon Corp now owns 26,148 shares of the company’s stock worth $335,000 after buying an additional 3,433 shares in the last quarter. Geode Capital Management LLC raised its stake in Protagonist Therapeutics by 1.9% in the first quarter. Geode Capital Management LLC now owns 101,218 shares of the company’s stock worth $1,296,000 after buying an additional 1,850 shares in the last quarter. State Street Corp raised its stake in Protagonist Therapeutics by 50.8% in the fourth quarter. State Street Corp now owns 92,163 shares of the company’s stock worth $2,028,000 after buying an additional 31,042 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Protagonist Therapeutics by 1.1% in the first quarter. Vanguard Group Inc. now owns 313,514 shares of the company’s stock worth $4,016,000 after buying an additional 3,435 shares in the last quarter. 47.57% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Protagonist Therapeutics (NASDAQ PTGX) opened at 10.55 on Monday. Protagonist Therapeutics has a one year low of $8.00 and a one year high of $26.36. The firm’s 50-day moving average is $10.32 and its 200-day moving average is $15.08. The stock’s market capitalization is $177.83 million.
Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Wednesday, May 10th. The company reported ($0.84) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by $0.23.
WARNING: “Protagonist Therapeutics, Inc. (PTGX) Short Interest Update” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/06/19/protagonist-therapeutics-inc-ptgx-sees-large-increase-in-short-interest-updated.html.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Stock Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related stocks with our FREE daily email newsletter.